Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for Cerebral Edema After ICH
NCT04088630Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fingolimod in intracerebral hemorrhage (ICH) and cerebral edema, sponsored by Wake Forest University Health Sciences. Primary endpoints: Number of Participants With Clinically Significant Cardiac Events at 30 days, Rate of Nosocomial Infections (UTI, Sepsis, and Pneumonia) at 90 days and 1 more. Started Aug 2020; status: completed.
02
Drugs
fingolimod
03
Conditions
intracerebral hemorrhage (ICH)cerebral edema
Beyond the preview
Go deeper on NCT04088630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088630.